EBSCN·2025-08-08 08:46Investment Rating - The report maintains an "Increase" rating for the companies involved in the brain-computer interface (BCI) industry, specifically recommending companies like Weisi Medical and Xiangyu Medical [5]. Core Insights - The recent "Implementation Opinions" issued by the Ministry of Industry and Information Technology and other ministries focus on five key tasks and three major projects aimed at accelerating the development of the BCI industry, with goals set for 2027 and 2030 [1][2]. - By 2027, the report anticipates achieving international advanced levels in electrodes, chips, and complete machines, as well as establishing 2-3 industrial development clusters [1]. - By 2030, the aim is to cultivate 2-3 global leading enterprises and build a competitive industrial ecosystem [1]. Summary by Sections Key Tasks and Projects - The five key tasks outlined include strengthening foundational software and hardware, creating high-performance products, promoting the application of technological achievements, expanding innovative entities, and enhancing industrial support capabilities [2]. - The three major projects consist of core software and hardware foundational projects, high-quality complete machine projects, and application expansion projects [2]. Local Action Plans - Local governments, such as Beijing and Shanghai, have introduced action plans to develop the BCI industry, with Beijing aiming to form an initial industrial ecosystem by 2030 and Shanghai targeting the completion of over five invasive and semi-invasive BCI products by 2027 [3]. - Sichuan Province plans to cultivate 10 leading enterprises and 200 innovative SMEs by 2030, with a target of performing 3,000 invasive BCI surgeries annually [3]. Product Development and Clinical Trials - The report notes that non-invasive BCI products are progressing rapidly, with several companies expected to receive approvals for their products in the second half of the year [4]. - Companies like Brain Tiger Technology and Ladder Medical are leading in the clinical trial progress for invasive and semi-invasive BCI products [4]. Investment Recommendations - The report recommends investing in companies that have early layouts in BCI products, such as Xiangyu Medical and Weisi Medical, while also suggesting attention to other companies like Chengyitong and Aipeng Medical [4].